Myriad Genetics Inc
MYGN6.550USD
-0.010-0.15%
收盘 12/24, 13:00（美东）报价延迟15分钟
609.80M总市值
亏损市盈率 TTM
关于 Myriad Genetics Inc 公司
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
Myriad Genetics Inc简介
公司代码MYGN
公司名称Myriad Genetics Inc
上市日期Oct 06, 1995
CEORaha (Samraat S)
员工数量2700
证券类型Ordinary Share
年结日Oct 06
公司地址322 North 2200 West
城市SALT LAKE CITY
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编84116
电话18015843600
网址https://myriad.com/
公司代码MYGN
上市日期Oct 06, 1995
CEORaha (Samraat S)
Myriad Genetics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Brian Donnelly
Mr. Brian Donnelly
Chief Commercial Officer
Chief Commercial Officer
397.53K
--
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer and Chief Commercial Officer
Chief Operating Officer and Chief Commercial Officer
220.57K
-0.49%
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
132.14K
+60.47%
Ms. Margaret (Maggie) Ancona
Ms. Margaret (Maggie) Ancona
Senior Vice President, Chief of Staff
Senior Vice President, Chief of Staff
127.73K
-0.74%
Ms. Rashmi Kumar
Ms. Rashmi Kumar
Independent Director
Independent Director
127.19K
+64.34%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
110.96K
+98.89%
Mr. Benjamin Richard (Ben) Wheeler
Mr. Benjamin Richard (Ben) Wheeler
Chief Financial Officer
Chief Financial Officer
92.65K
-2.69%
Dr. Dale Muzzey
Dr. Dale Muzzey
Chief Scientific Officer
Chief Scientific Officer
45.88K
-46.96%
Ms. S. Louise Phanstiel, CPA
Ms. S. Louise Phanstiel, CPA
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Matt Scalo
Mr. Matt Scalo
Investor Relations
Investor Relations
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Brian Donnelly
Mr. Brian Donnelly
Chief Commercial Officer
Chief Commercial Officer
397.53K
--
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer and Chief Commercial Officer
Chief Operating Officer and Chief Commercial Officer
220.57K
-0.49%
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
132.14K
+60.47%
Ms. Margaret (Maggie) Ancona
Ms. Margaret (Maggie) Ancona
Senior Vice President, Chief of Staff
Senior Vice President, Chief of Staff
127.73K
-0.74%
Ms. Rashmi Kumar
Ms. Rashmi Kumar
Independent Director
Independent Director
127.19K
+64.34%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
110.96K
+98.89%
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
业务USD
名称
营收
占比
Hereditary Cancer
96.30M
45.19%
Prenatal
47.60M
22.34%
Pharmacogenomics
37.80M
17.74%
Tumor Profiling
31.40M
14.73%
地区USD
名称
营收
占比
United States
198.20M
93.01%
Rest of world
14.90M
6.99%
业务
地区
业务USD
名称
营收
占比
Hereditary Cancer
96.30M
45.19%
Prenatal
47.60M
22.34%
Pharmacogenomics
37.80M
17.74%
Tumor Profiling
31.40M
14.73%
股东统计
更新时间: 11月18日 周二
更新时间: 11月18日 周二
持股股东
股东类型
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
14.22%
The Vanguard Group, Inc.
8.34%
State Street Investment Management (US)
5.34%
Millennium Management LLC
5.09%
Glenview Capital Management, LLC
4.92%
其他
62.09%
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
14.22%
The Vanguard Group, Inc.
8.34%
State Street Investment Management (US)
5.34%
Millennium Management LLC
5.09%
Glenview Capital Management, LLC
4.92%
其他
62.09%
股东类型
持股股东
占比
Investment Advisor
37.68%
Investment Advisor/Hedge Fund
27.22%
Hedge Fund
25.48%
Research Firm
5.93%
Individual Investor
3.28%
Pension Fund
1.73%
Bank and Trust
0.41%
Family Office
0.24%
Sovereign Wealth Fund
0.04%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
518
92.00M
98.69%
-11.12M
2025Q2
518
100.80M
108.34%
-1.85M
2025Q1
527
99.14M
107.57%
-4.54M
2024Q4
516
96.89M
106.12%
-1.41M
2024Q3
505
95.02M
104.61%
-5.50M
2024Q2
486
96.79M
106.52%
-6.22M
2024Q1
460
98.19M
108.68%
+613.48K
2023Q4
464
93.46M
105.77%
+2.70M
2023Q3
471
86.01M
104.78%
-3.73M
2023Q2
480
84.60M
103.32%
-6.34M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
BlackRock Institutional Trust Company, N.A.
13.43M
14.43%
-416.99K
-3.01%
Jun 30, 2025
The Vanguard Group, Inc.
9.15M
9.83%
-1.47M
-13.83%
Jun 30, 2025
State Street Investment Management (US)
4.81M
5.17%
-458.84K
-8.71%
Jun 30, 2025
Millennium Management LLC
4.92M
5.29%
+855.19K
+21.01%
Jun 30, 2025
Glenview Capital Management, LLC
4.59M
4.93%
+687.86K
+17.64%
Jun 30, 2025
D. E. Shaw & Co., L.P.
4.51M
4.85%
+1.99M
+78.84%
Jun 30, 2025
Morgan Stanley & Co. LLC
3.37M
3.63%
+1.97M
+140.14%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.22M
2.39%
-7.80K
-0.35%
Jun 30, 2025
Camber Capital Management LP
2.00M
2.15%
-350.00K
-14.89%
Jun 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
Global X Genomics & Biotechnology ETF
0.8%
Invesco NASDAQ Future Gen 200 ETF
0.68%
Federated Hermes MDT Small Cap Core ETF
0.5%
Invesco S&P SmallCap Health Care ETF
0.46%
State Street SPDR S&P Biotech ETF
0.24%
Strategas Global Policy Opportunities ETF
0.22%
Inspire Small/Mid Cap ESG ETF
0.22%
Direxion Daily S&P Biotech Bull 3X Shares
0.14%
Vanguard US Quality Factor ETF
0.14%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.12%
查看更多
Global X Genomics & Biotechnology ETF
占比0.8%
Invesco NASDAQ Future Gen 200 ETF
占比0.68%
Federated Hermes MDT Small Cap Core ETF
占比0.5%
Invesco S&P SmallCap Health Care ETF
占比0.46%
State Street SPDR S&P Biotech ETF
占比0.24%
Strategas Global Policy Opportunities ETF
占比0.22%
Inspire Small/Mid Cap ESG ETF
占比0.22%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.14%
Vanguard US Quality Factor ETF
占比0.14%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
占比0.12%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
Myriad Genetics Inc的前五大股东是谁？
Myriad Genetics Inc 的前五大股东如下：
BlackRock Institutional Trust Company, N.A.持有股份：13.43M，占总股份比例：14.43%。
The Vanguard Group, Inc.持有股份：9.15M，占总股份比例：9.83%。
State Street Investment Management (US)持有股份：4.81M，占总股份比例：5.17%。
Millennium Management LLC持有股份：4.92M，占总股份比例：5.29%。
Glenview Capital Management, LLC持有股份：4.59M，占总股份比例：4.93%。
BlackRock Institutional Trust Company, N.A.持有股份：13.43M，占总股份比例：14.43%。
The Vanguard Group, Inc.持有股份：9.15M，占总股份比例：9.83%。
State Street Investment Management (US)持有股份：4.81M，占总股份比例：5.17%。
Millennium Management LLC持有股份：4.92M，占总股份比例：5.29%。
Glenview Capital Management, LLC持有股份：4.59M，占总股份比例：4.93%。
Myriad Genetics Inc的前三大股东类型是什么？
Myriad Genetics Inc 的前三大股东类型分别是：
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
State Street Investment Management (US)
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
State Street Investment Management (US)
有多少机构持有Myriad Genetics Inc(MYGN)的股份？
截至2025Q3，共有518家机构持有Myriad Genetics Inc的股份，合计持有的股份价值约为92.00M，占公司总股份的98.69%。与2025Q2相比，机构持股有所增加，增幅为-9.65%。
哪个业务部门对Myriad Genetics Inc的收入贡献最大？
在FY2025Q2，Hereditary Cancer业务部门对Myriad Genetics Inc的收入贡献最大，创收96.30M，占总收入的45.19%。
